Unless someone presents a compelling reason to sell. After a sharp decline in value, it has entered a recovery phase. Its movement largely mirrors overall market trends influenced by tariffs, rather than showing individual volatility that might suggest underlying weakness.
One of Moderna's key strengths is its strong diversification, supported by solid R&D. The main concern, however, is whether it's overly dependent on materials imported from China.